Overproduction of N(epsilon)-(carboxymethyl)lysine-induced neovascularization in cultured choroidal explant of streptozotocin-diabetic rat.
Action of N(epsilon)-(carboxymethyl)lysine (CML) adduct, an advanced glycation end product, was investigated on neovascularization of cultured choroidal explants in streptozotocin (STZ)-diabetic rat. The choroidal explants of early (4 weeks after an injection of 60 mg/kg STZ) and advanced (8 months after the STZ injection) diabetic rats, and age-matched normal rats were cultured in fibrin gel with Dulbecco's modified Eagle medium containing fetal bovine serum. The number of budded microvessel-like structures was counted and used as an index of in vitro neovascularization. Choroidal explants in the early diabetic stage released vascular endothelial growth factor (VEGF) and tended to increase tumor necrosis factor (TNF) alpha and platelet-derived growth factor (PDGF)-B, and concomitantly facilitated growth of sprout and buds, compared to the normal control. When choroidal explants were stimulated with CML-human serum albumin (HSA), its releasing effect was in the order VEGF>TNFalpha>PDGF-B. CML-HSA and CML-bovine serum albumin augmented the neovascularization in the cultured diabetic explant and their actions did not virtually differ. A monoclonal anti-CML antibody (6D12) inhibited the neovascularization in the advanced diabetes greater than that in the early diabetes. Inhibitory actions of anti-VEGF and anti-TNFalpha antibodies on the neovascularization were similar to that of the anti-CML antibody in the diabetes. In conclusion, CML adducts were accumulated and over-produced the actions of VEGF, TNFalpha and PDGF-B in the choroidal explant during diabetes in an age-dependent manner. TNFalpha and VEGF are likely to play a predominant role for the CML-induced choroidal neovascularization.
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanagawa-Machi, Kanazawa, Japan. s-kobayashi@hokuriku-u.ac.jp
Shinjiro
S
Kobayashi
Miho
M
Suzuki
Hiroshi
H
Tsuneki
Ryoji
R
Nagai
Seikoh
S
Horiuchi
Nobuyoshi
N
Hagino
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D002829:Choroid / Q000098:blood supply* / Q000378:metabolism; D020256:Choroidal Neovascularization / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives* / Q000096:biosynthesis* / Q000737:chemistry / Q000276:immunology; D008297:Male; D010982:Platelet-Derived Growth Factor / Q000819:agonists; D051381:Rats; D017208:Rats, Wistar; D012709:Serum Albumin / Q000737:chemistry; D013311:Streptozocin; D013997:Time Factors; D046509:Tissue Culture Techniques; D014409:Tumor Necrosis Factor-alpha / Q000819:agonists / Q000276:immunology; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology / Q000378:metabolism
D000911:Antibodies, Monoclonal; D010982:Platelet-Derived Growth Factor; D012709:Serum Albumin; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D013311:Streptozocin; C048496:N(6)-carboxymethyllysine; D008239:Lysine